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Key Points
• Confirms the prognostic effect
of NOTCH1 mutations in
pediatric T-cell lymphoblastic
lymphoma in a large and
independent cohort.
• Provides the scientific basis
for using NOTCH1 mutations
and chromosome 6q
alterations as stratification
criterion in patients with T-cell
lymphoblastic lymphoma.
Probability of event-free survival (pEFS) in pediatric T-cell lymphoblastic lymphoma is
about 80%, whereas survival in relapsed patients is very poor. No stratification criteria
have been established so far. Recently, activating NOTCH1 mutations were reported
to be associated with favorable prognosis, and loss of heterozygosity at chromosome
6q (LOH6q) was reported to be associated with increased relapse risk. The current
project was intended to evaluate the prognostic effect of these markers. Mutations in
hot spots of NOTCH1 and FBXW7 were analyzed in 116 patients. Concerning LOH6q
status, 118 patients were investigated, using microsatellite marker analysis, in
addition to an earlier reported cohort of 99 available patients. Ninety-two cases were
evaluable for both analyses. All patients were treated with T-cell lymphoblastic
lymphoma-Berlin-Frankfurt-Mu¨nster group (BFM)-type treatment. LOH6q was ob-
served in 12% of patients (25/217) and associated with unfavorable prognosis (pEFS
27% 6 9% vs 86% 6 3%; P < .0001). In 60% (70/116) of the patients, NOTCH1 mutations
were detected and associated with favorable prognosis (pEFS 84% 6 5% vs 66% 6
7%; P = .021). Interestingly, NOTCH1 mutations were rarely observed in patients with
LOH in 6q16. Both prognostic markers will be used as stratification criteria in coming Non-Hodgkin Lymphoma-BFM trials.
(Blood. 2013;121(16):3153-3160)
Introduction
Lymphoblastic T-cell lymphoma (T-LBL) is the second most
common subtype of non-Hodgkin lymphoma (NHL) in children
and adolescents. With current treatment regimens, event-free
survival (EFS) rates of 75% to 85% are achieved.1-7 Despite these
acceptable EFS rates, concepts of risk-adjusted treatment could not
be realized because of the lack of prognostic parameters. However,
such parameters are highly needed, as survival rates in relapsed
patients with T-LBL are only about 10%,8 and therefore identiﬁcation
of high-risk patients for targeted treatment intensiﬁcation is desired
to prevent relapses. In contrast, current treatment regimens are asso-
ciated with signiﬁcant acute and long-term toxicity, which might be
avoidable if treatment intensity can be reduced for low-risk patients
without affecting the outcome. Apart from stage of disease at di-
agnosis, which is an insufﬁcient parameter for T-LBL, as more than
95% of patients are diagnosed with advanced stages of disease, no
clinical parameter for treatment stratiﬁcation could be validated
to date.
Little is known about the pathogenesis and genetic changes in
pediatric T-LBL, mostly because of the lack of adequate samples
for biological research. In recent studies, activating mutations of
NOTCH1 and/or FBXW7 (N/Fpos) have been observed in about
50% of pediatric patients with T-cell lymphoblastic leukemia
(T-ALL; for a complete overview of publications dealing with this
topic, see supplemental Table 1 on the Blood website).9-19 The
evolutionary highly conserved NOTCH1 signaling pathway is
involved in the regulation of many cellular processes; for example,
early T-cell development.20,21 The transmembrane protein NOTCH1
is activated by the contact of NOTCH1-ligands (Delta-like 1-4,
Jagged1, or Jagged2), which trigger the proteolytic cleavages
releasing the protein’s active part, intracellular NOTCH1
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(ICN1).20,21 ICN1 translocates to the nucleus, where it acts as part
of a transcriptional complex regulating the expression of diverse
target genes. The ICN1 level in the cell is decreased by degradation
through ubiquitination. The responsible E3 ubiquitin ligase is the
tumor suppressor FBXW7.20,21 The reported mutations occur in
well-described hot spots in speciﬁc exons, leading to increased ICN1
in T-ALL cell lines9,22,23 and primary T-ALL cells.14 Until now,
only 4 studies analyzed pediatric patients with T-LBL, including
fewer than 90 patients in total (supplemental Table 1).11,17,24,25
Other genetic markers that might be of prognostic relevance are
alterations of chromosome 6q. In previous studies, we could show
in a limited test cohort of patients that loss of heterozygosity (LOH)
at chromosome 6q14-24 (LOH6q) is associated with a signiﬁcantly
increased risk for relapse.26,27 Therefore, NOTCH1 and/or FBXW7
mutations, as well as alterations of chromosome 6q, are candidate
genetic markers with potential prognostic relevance in pediatric
T-LBL. To validate their effect in conjunction with NHL-Berlin-
Frankfurt-Mu¨nster group (BFM) treatment strategies, we analyzed
a large cohort of uniformly treated patients. The prognostic
relevance of both alterations for pediatric patients suffering from
T-LBL is presented, which will be the scientiﬁc basis for the
implementation of both molecular markers as stratiﬁcation criteria
in upcoming clinical trials of the NHL-BFM study group.
Methods
Patients
Between April 1995 and July 2012, a total of 438 pediatric patients with T-
LBL were registered in the NHL-BFM study center after written informed
consent. Lymphoma and germline material sufﬁcient for DNA isolation for
LOH analysis was available from 217 of these patients. Lymphoma material
sufﬁcient for DNA isolation for analysis of NOTCH1 and/or FBXW7 was
available from 116 of the patients. A total of 241 representative pediatric
patients with T-LBL have been analyzed, with clinical characteristics
similar to those of the 197 patients who did not have adequate material. The
only exceptions were the younger age in the analyzed cohort and the poorer
general conditions at diagnosis in all analyzed patients and the patients
analyzed for NOTCH1 and FBXW7 (Table 1). For the trials NHL-BFM 95
and EURO-LB 02, in which patients were recruited, the accompanying
molecular research on pediatric LBL has been approved by the ethical
committees of the Hannover Medical School and Justus-Liebig University
Giessen, Germany. These studies were conducted in accordance with the
Declaration of Helsinki.
Diagnosis and therapy
Diagnosis of T-LBL cases was carried out according to World Health
Organization Classiﬁcation of Hematological Malignancies and recom-
mendations from the European childhood lymphoma pathology panel.28,29
Patients were treated according to an ALL-BFM-type treatment strategy
for LBL, as described previously.2
Mutational analysis of NOTCH1 and/or FBXW7
Lymphoma DNA at the time of initial diagnosis was isolated from frozen
cells (tumors or pleural/pericardial effusions) or parafﬁn-embedded tumor
biopsies. Mutational hot spots were ampliﬁed using standard polymerase
chain reaction (PCR) conditions and OneTaq Hot Start 23 Master Mix
(New England Biolabs, Frankfurt/Main, Germany). Primers (sequences given
in supplemental Table 2) were synthesized by Euroﬁns MWG Operon
(Ebersberg, Germany). PCR products were sequenced by LGC Genomics
(Berlin, Germany) or on an ABI 3130xl Genetic Analyzer (Life Technologies,
Darmstadt, Germany), either directly or after subcloning into Topo TA cloning
vectors (Life Technologies, Darmstadt, Germany). Base-pair substitutions were
veriﬁed twice, and frameshift mutations once.
LOH analysis
LOH analysis was carried out essentially as described previously.27 Cases
with fewer than 3 informative results were excluded because of insufﬁcient
DNA quantity and/or quality. LOH positivity was deﬁned as at least 2
adjacent informative microsatellite markers with LOH. LOH data on 108
patients have been reported previously26,27; because of the lack of adequate
material for validation, data of 9 patients have been excluded, and the
remaining 99 patients represent the test cohort.
Statistical analysis
Probability of EFS (pEFS) was calculated according to Kaplan and Meier30
with differences compared by log-rank test.31 pEFS was calculated from the
date of diagnosis to ﬁrst event (death from any cause, relapse, resistant
disease, or second malignancy) or to the date of last follow-up. Patients
lost to follow-up were censored at date of last follow-up-examination.
Cumulative incidence functions for relapse were constructed by the method
of Kalbﬂeisch and Prentice32 and compared with Gray’s test.33 Differences
in the distribution of individual parameters among patient subsets were
analyzed using the x2 test or Fisher’s exact test. Multivariate analyses were
calculated using standard methods.34
Results
Five-year pEFS was 80% 6 2% for the total cohort of 438 patients.
For the 241 evaluable patients with T-LBL, pEFS was 80%6 3%, for
the 116 patients with investigated NOTCH1 and/or FBXW7 status it
was 77% 6 4%, and for the 217 patients with investigated LOH6q
status it was 79%6 3%. The median follow-up was 5.5 years for the
entire group. In line with the treatment regimen, 6 of 241 analyzed
patients (6/217 in LOH6q group and 3/116 in NOTCH1/FBXW7
group) received intensiﬁed high-risk courses analog to the ALL-BFM
protocol because of insufﬁcient tumor response at day 33 of induction.
Clinical characteristics for all analyzed patients are given in Table 1.
NOTCH1 and FBXW7 analyses
Six exons, which have been identiﬁed as mutational hot spots in
pediatric T-ALL,9-19 were sequenced: for NOTCH1, exons 26
(encoding the N-terminal part of the heterodimerization [HD]
domain), 27 (encoding the C-terminal part of the HD domain), and
34 (encoding the transactivation domain (TAD) and PEST domain
(sequence rich in proline [P], glutamic acid [E], serine [S] and
threonine [T]); ampliﬁcation in fragments 34a, 34b, and 34c); and for
FBXW7, exons 9, 10, and 12 (all 3 encoding fragments of the 8 WD40
domains). Sequencing was successful in 116 pediatric patients with T-
LBL, with evaluable sequences of all PCRs for 112 cases and of all
PCRs except NOTCH1-exon 34a because of insufﬁcient ampliﬁcation
of minor-quality DNA for 4 cases. In 70 of 116 cases (60%),
mutations in NOTCH1 could be identiﬁed: 46 cases showed mutations
in exon 26 (66%), 13 in exon 27 (19%), 2 in the TAD domain (3%),
and 26 in the PEST domain (37%) (Figure 1).35 In 2 cases, mutations
in exons 26 and 27 were detectable concurrently; in 13 cases, mutations
in exons 26 and 34; and in 2 cases, mutations in exons 27 and 34.
Twenty-one (18%) of the 116 analyzed patients showed
mutations in FBXW7: 14 in exon 9 (67%), 6 in exon 10 (29%)
and 4 in exon 12 (19%) (supplemental Figure 1). Two cases had
mutations both in exons 9 and 10, and 1 patient had mutations in
exons 9 and 12. Seventeen (15%) of 116 patients showed mutations
in both genes; in a single case, mutations occurred in parallel in the
PEST domain of NOTCH1 and in FBXW7. There, the mutation in
FBXW7-exon 12 was a frameshift instead of the normally
occurring missense mutations. Included in the total of 91 detected
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aberrations are 3 synonymous mutations: 1 each in exon 26, exon
27, and the TAD (Figure 1). A detailed overview of the identiﬁed
aberrations is given in supplemental Figure 2.
The clinical features of the 74 N/Fpos patients were similar to
those of the 42 patients without NOTCH1 and/or FBXW7 mutations
(N/Fneg); the only exception was the overrepresentation of younger
patients in the N/Fpos group (Table 1). The signiﬁcant correlation
of both, the 5-year pEFS (84% 6 5% in NOTCH1 mutated [Npos]
patients vs 66% 6 7% in NOTCH1 nonmutated [Nneg] patients;
P 5 .021) and the 5-year cumulative incidence (CI) of nonresponse/
progression/relapse (15% 6 5% in Npos compared with 27% 6 7%
in Nneg; P 5 .05), showed the prognostic effect of NOTCH1
mutations within our cohort (Figure 2).
Similar results were observed taking into account NOTCH1
and/or FBXW7 mutations (supplemental Figure 3) but not
regarding FBXW7 mutations alone (supplemental Figure 4). pEFS
was also calculated according to the underlying mutations: In our
cohort of 116 analyzed patients, no prognostic relevance of the
position of mutation could be conﬁrmed (Table 2). Data from
subgroup analyses according to treatment protocols are given in
supplemental Table 3.
LOH analyses
Fragment-length analysis of germline and corresponding tumor
DNA from a total of 217 patients with T-LBL (99 patients of the
test cohort26,27 and 118 new patients of the validation cohort) was
successful for a total of 4058 marker analyses, with LOH in 206
markers, retention of heterozygous patterns in 2680 markers, ho-
mozygous patterns in 1090 markers, and microsatellite instability
in 82 markers. LOH of at least 2 neighboring markers (separation
by any result but retention of heterozygosity permitted) was detected
in 25 (12%) of the analyzed 217 cases. In 4 cases, LOH affected all
informative markers, whereas interstitial regions of LOH were
detected in the remaining 21 patients. In 2 cases, 2 regions of LOH
were identiﬁed. According to previous ﬁndings, in 22 of the 25 cases
the putative LOH region included at least one of the adjacent
markers D6S1284, D6S1716, and D6S1717 on chromosomal band
6q16, representing the common deleted region (supplemental
Figure 5). Clinical characteristics were similar in the 25 LOH6q-
positive (LOH6qpos) patients compared with the 192 LOH6q-negative
patients (LOH6qneg; Table 1).
In the outcome analysis, LOH6qpos was associated with a sig-
niﬁcantly inferior 5-year pEFS of 27% 6 9% compared with 86% 6
3% for LOH6qneg cases (P , .0001). This was mainly because of an
increased CI of nonresponse/progression/relapse being 69%6 10% in
LOH6qpos vs 12% 6 2% in LOH6qneg (P , .0001) (Figure 3). There
was no difference in the pEFS (80%6 4% vs 79%6 4%;P5 .92) and
CI of nonresponse/progression/relapse (18%6 4% vs 18%6 4%; P5
.96) between the 99 patients of the test cohort and the 118 patients of the
validation cohort. Data concerning pEFS of subgroups according to
treatment protocol are given in supplemental Table 3.
Figure 1. Overview about the mutations found in NOTCH1. The domain structure of NOTCH1, the functions of these domains, and the respective coding exons are
schematically depicted (A). Analyzed exons and domains are highlighted. Mutations detected in this study are illustrated with respect to their position in the exons of the gene
(B). Symbols below the exon line indicate homozygous mutation. Modified after Weng et al9, Zuurbier et al14, and Wagener and Mu¨ller.35 EGF, epidermal growth factor; HD,
heterodimerization domain; LNR, LIN12/NOTCH repeats; NLS, nuclear localization sequence; TAD, transactivation domain. TM, transmembrane domain.
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NOTCH1/FBXW7 and LOH6q
In 92 patients, adequate material was available to perform both
genetic marker studies. Fifty-three of 92 cases were Npos, whereas
LOH6qpos was detected in 11 of 92 patients. Except in 3 cases, both
genetic alterations did not occur in parallel (P[Fisher’s Exact] 5
.033). In 2 of 3 cases, LOH at chromosome 6q did not span the
chromosomal region 6q16 potentially relevant for unfavorable
outcome. As a consequence, only 1 of 92 patients showed in parallel
a favorable activating NOTCH1 mutation together with a poor pro-
gnostic LOH6q16. NOTCH1 mutations were not generally associated
with a reduced incidence of deletions or LOH. The incidence of
LOH of chromosome 9p at the locus of CDKN2A and CDKN2B,
which has been investigated previously,36 was observed in 16 of 26
Npos cases compared with 7 of 16 Nneg cases (P[Fisher’s Exact] 5
.21). Of these 92 patients with results of both experimental analyses,
81 cases were LOH6qneg and 11 cases were LOH6qpos. Data con-
cerning outcome analysis of this subgroup are given in supple-
mental Table 3.
Within the cohort, 8 (21%) of 39 cases were Nneg and LOH6qpos,
whereas only 3 (6%) of 53 cases were Npos and LOH6qpos
concurrently. To exclude a dependency of both markers and to
evaluate the strength of their predicting relevance, LOH6q status,
NOTCH1 status, and FBXW7 status were subjected to a multivariate
analysis, together with the clinical parameter “general condition at
diagnosis.” Poor performance status, deﬁned as a Karnofsky score
between 0% and 20%, was associated with unfavorable pro-
gnosis in pediatric patients with T-LBL of the NHL-BFM group
in a univariate analysis (B.B., M.Z., and A.R., unpublished results).
Within this multivariate analysis, both LOH6q status and NOTCH1
mutation status remained independent prognostic factors (Table 3).
Discussion
Gaining an insight into the genetic ﬁeld of pediatric T-LBL is ham-
pered by the scarcity of patient material for molecular biological
research. Until now, no biological marker could be validated as a
prognostic parameter for treatment stratiﬁcation. Thus, the primary
objective of this study was to search for valid stratiﬁcation criteria
for patients with T-LBL. Here, we analyzed the mutational status in
Table 2. Overview about pEFS at 5 years, according to position of
mutations
Position of mutation
Number of
patients with the
respective mutation
pEFS at
5 years
Only in HD domain 27 92% 6 5%
Only in PEST domain 11 76% 6 15%
Only in HD 1 PEST domain 14 85% 6 10%
Only in FBXW7 4 75% 6 22%
Only in HD 1 FBXW7 15 76% 6 12%
P(Log-Rank) 5 .89; not considered for calculation are 1 case with a single
mutation in TAD, 1 case with mutations in TAD and FBXW7, and 1 case with
mutations in HD, PEST domain, and FBXW7.
Figure 2. Five-year probability of EFS (A) and 5-year cumulative incidence of
nonresponse/progression/relapse (B), according to NOTCH1 mutational
status.
Figure 3. Five-year probability of EFS (A) and 5-year cumulative incidence of
nonresponse/progression/relapse (B), according to LOH6q status.
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hot spots of NOTCH1 and FBXW7 and copy number alterations on
chromosome 6q14-24 in a total of 241 pediatric patients with T-LBL.
This cohort of patients, which is to our knowledge the largest series of
pediatric T-LBL available for molecular genetic studies so far, was
registered in the NHL-BFM study center and uniformly diagnosed and
treated according to NHL-BFM treatment strategies. The current study
validated LOH6qpos as a poor-prognosis marker (5-year pEFS 27%6
9% vs 86% 6 3% in LOH6qneg patients) within 217 investigated
patients. This conﬁrms that the unfavorable prognosis that was reported
previously is indeed associated with the patients with T-LBL of the
NHL-BFM studies and not a result of any bias in sample selection. The
strength of this marker is also its very high signiﬁcance (P , .0001).
Until now, we have not been aware of any molecular or clinical
marker distinguishing 2 prognostic groups in pediatric T-LBL with
such strength. These results are so convincing that the LOH6q status
will serve as a stratiﬁcation criterion to identify very high risk
patients in future clinical trials with involvement of the NHL-BFM
group. With the help of this marker, a subgroup of less than 15% of
patients can be deﬁned in which more than 40% of relapses occur.
Reducing the incidence of relapse in this small subgroup will have
signiﬁcant effect on the pEFS of the whole cohort.
Concerning NOTCH1 and/or FBXW7 mutation status, 4 papers
were published including 54, 14, 11, and 9 pediatric patients with
T-LBL.11,17,24,25 This study, which included 116 evaluable patients,
strengthened the input to that ﬁeld. The detected mutations in the
current study were mainly either mismatch mutations or small in-
frame deletions/insertions in the HD domain and nonsense or
frameshift mutations in the PEST domain of NOTCH1, as well
as mismatch mutations affecting 3 essential positions within the
canonical binding pocket of FBXW7.23,37 This was in agreement
with the published data in pediatric T-LBL.
More is known about the frequency, type, and prognostic
relevance of NOTCH1 and/or FBXW7 mutations in pediatric patients
with T-ALL.9-19 T-LBL and T-ALL are often considered to be closely
related or 2 manifestations of 1 disease; however, recent publications
provide evidence for molecular differences between them.24,27,38-42
Among others, differences in the common deleted region and, most
likely because of that, in the prognostic effect of chromosome 6q
alterations between T-ALL and T-LBL are described.27 This might be
a distinguishing feature between both T-ALL and T-LBL and may be
relevant with regard to the different clinical manifestations.
Comparison of the incidence, type, and position of NOTCH1
and/or FBXW7 mutations obtained in the current study with the
published data on T-ALL revealed no difference between the 2
diseases. This ﬁts with the common understanding that the NOTCH1
pathway is responsible for early T-cell development, which is dis-
turbed both in T-ALL and T-LBL. Several studies indicate a favorable
prognosis for patients with T-ALL with the NOTCH1 mutation
compared with nonmutated patients9-19 (supplemental Table 1).
However, available data on T-ALL are not absolutely consistent, as
the effect of the mutation might depend on the applied treatment.
The analyses of the 116 T-LBL reported here also showed a fa-
vorable prognosis for Npos cases.
The data presented are very similar to those reported for
pediatric patients with T-ALL who were treated according to the
ALL-BFM treatment regimen,10,15 which is comparable to the
treatment administered to patients with T-LBL from the NHL-
BFM group. In their hands, the favorable prognostic relevance of
NOTCH1 mutations can be separated from the relevance of
FBXW7 mutations too, as observed in our cohort. This supports
the hypothesis of the prognostic effect of activating NOTCH1
mutations being inﬂuenced by the applied treatment. Further-
more, it conﬁrms that in the context of BFM-type treatment,
NOTCH1 mutations can be used as a prognostic marker to
subgroup patients into risk groups.
The diverging distances between the 5-year pEFS (84% 6 5%
vs 66% 6 7%) and the 5-year CI of nonresponse/progression/
relapse (15% 6 5% vs 27% 6 7%) could be suggestive of a higher
nonrelapse mortality rate in Npos patients. However, as it is
depicted in Table 1, rates for treatment-related mortality, death, or
secondary malignancies are similar between Npos and Nneg patients.
A recent report on patients with T-ALL showing an inverse as-
sociation between the strength of the NOTCH1 and/or FBXW7
mutation and the strength of the favorable prognostic relevance14
could not be conﬁrmed in the current cohort of pediatric patients with T-
LBL. Thismight be explained by signiﬁcant differences in the treatment
administered to the patients with T-LBL in the current study and the
patients with T-ALL in the cited manuscript Dutch Childhood
OncologyGroup,whichmodify the prognostic effect to a certain extent.
The way NOTCH1 and/or FBXW7 mutations alter the chemo-
sensitivity of the cells is not yet understood. To our knowledge,
only a single study reported upregulation of several chemotherapy-
relevant genes modulating the response to methotrexate, doxoru-
bicin, vincristine, 6-mercaptopurine, and L-asparaginase in N/Fpos
cases of pediatric T-ALL.12 Thus, the effect of modulated chemo-
sensitivity of N/Fpos patients might depend on the polychemother-
apy regimen concerning selection, dose, and schedule of drug
administration. Further analyses and a search for mutations in genes
involved in regulation of chemoresistance are inevitable to clarify
the underlying mechanisms.
In the current study, almost 100 cases were available for both
LOH6q and NOTCH1 and/or FBXW7 analyses. Interestingly, only
3 cases were observed in which both alterations were detectable; in
addition, in 2 of the 3 cases, LOH6q did not span the chromosomal
band 6q16, which has been described as the critical region of LOH
associated with poor outcome in T-LBL (supplemental Figure 5).26,27
As a consequence, only a single patient could be identiﬁed in whom
both genetic alterations with opposite prognostic association could
be observed. This patient received standard treatment and died 28
months after initial diagnosis because of multiple relapses. Except in
this single case, good prognostic NOTCH1mutations and poor prog-
nostic LOH6q16 seem to occur mutually exclusive. In the multivariant
analysis including the potential prognostic parameters LOH6q status,
NOTCH1 status, and FBXW7 status and the general condition at
diagnosis, both LOH6q status and NOTCH1 status turned out to be
independent prognostic parameters, whereas general condition at
diagnosis lost signiﬁcance (Table 3). This observation strengthens
the biological relevance of these 2 markers.
There are 2 hypotheses to explain the phenomenon of mutually
exclusive genetic events in cancer cells: ﬁrst, that these events are
Table 3. Multivariate analysis of pEFS at 5 years for LOH6q status,
NOTCH1 status and FBXW7 status and general condition at
diagnosis
Parameters HR LL UL p(x)
General condition at diagnosis 0.93 0.27 3.23 0.907
LOH6q 2.79 1.08 7.21 0.035
NOTCH1 mutation 0.36 0.14 0.91 0.031
FBXW7 mutation 1.13 0.31 4.09 0.854
HR, hazard ratio; LL, lower limit; UL, upper limit.
A Cox proportional hazards model was used to obtain the estimates and the 95%
confidence interval of the relative risk for prognostic factors. In multivariate analysis
considering general condition at diagnosis, which is itself a statistically significant
poor-prognosis parameter in pediatric T-LBL (B.B., M.Z., and A.R., unpublished
data), the parameters LOH6q and mutation in NOTCH1 remain significant.
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genetically redundant,43,44 which can also mean that they supply
the same selective pressure for clonal expansion,45 and second, that
both events confer drawbacks to these cells.43 Transferred into
pediatric T-LBL, the exclusive occurrence of NOTCH1 mutations
and LOH6q16 might be explained by the loss of a gene or
regulatory region in 6q16 acting in the NOTCH1 pathway.
Candidates might be POU3F2, which is described as an activator
of the NOTCH1 pathway in melanoma cells46; FBXL4, which,
similar to FBXW7, is a member of the F-box protein family; and
UFL1, which is involved in regulation of the NFkB pathway.47
NFkB itself is involved in T-cell development and regulated by the
NOTCH1 pathway.20,47,49 Concerning the second hypothesis, the
transfer of survival drawbacks or the provision of proapoptotic
signals to the cell, putative candidates in 6q16 are suggested to be
either involved in tumorigenesis or implicated in a wide range of
highly relevant cellular processes. Examples are the tumor suppressor
protein TSG1; the G protein–coupled receptors GPR63 and MCHR2;
2 proteins that are involved in the mitochondrial respiratory chain
(namely, NDUFAF4 and COQ3); CCNC, which encodes cyclin C
regulating the quiescence of human hematopoietic stem/progenitor
cells50; and the DNA repair protein MMS22L.
It would be interesting to analyze the association of the described
genetic alterations with early treatment response, especially as
insufﬁcient response after induction is the only indication for
treatment intensiﬁcation in the current NHL-BFM protocol. However,
the 6 patients fulﬁlling this criterion (6/217 patients in the LOH6q
group and 3/116 patients in the NOTCH1/FBXW7 group) are far too
few to allow the performance of valid and meaningful statistical tests.
Unfortunately, in the current NHL-BFM protocols, neither positron
emission tomography–computed tomography nor ﬂow minimal
residual disease/minimal disseminated disease analyses are included,
so these questions need to be solved prospectively.
Very recently, a study was published by E. Macintyre’s group
dealing, among other things, with the analysis of mutations in
NOTCH1 and/or FBXW7 and the deletion of CASP8AP2 (also
known as FLASH) at chromosome 6q15.25 Fifty-ﬁve percent of 54
pediatric patients with T-LBL, having also received a uniformly
BFM-type therapy, were N/Fpos, which was signiﬁcantly associated
with a more favorable outcome. Monoallelic deletions of CASP8AP2
could be observed in 18% of cases but did not display any prog-
nostic signiﬁcance. The current report conﬁrms relevant ﬁndings
concerning the prognostic effect of NOTCH1 mutations in an
independent cohort. Importantly, the present study analyzed more
than twice as many patients, and thus provided a much broader,
more detailed, and more meaningful insight into this matter.
In conclusion, the present study reports mutations in NOTCH1
and/or FBXW7 as well as the status of LOH6q in the largest series
of pediatric patients with T-LBL published to date. The 2 genetic
variations seem to occur mutually exclusive and are both asso-
ciated with the outcome of the patient, albeit with the opposite
effect. Although the prognostic relevance of LOH6q seems to be
stronger than the one of NOTCH1 mutational status, the difference
in pEFS according to NOTCH1 status is statistically signiﬁcant,
and the number of analyzed patients is large enough. Thus, the
available data from our own group presented in this manuscript,
together with the published data in the literature, are so convincing
that the NHL-BFM group aims at implementing these genetic
markers as stratiﬁcation criteria into the next treatment protocol.
The prognostic power of both markers will be reﬂected by a
gradual modiﬁcation of the treatment plan: Nneg cases will receive
moderate treatment intensiﬁcation, whereas LOH6qpos cases will
receive relevant treatment intensiﬁcation.
Thus, our current manuscript presents the scientiﬁc basis for 2
different molecular prognostic markers that will be used for
stratiﬁcation in the next clinical trials of the NHL-BFM group. This
will help improve the prognosis of pediatric patients with T-LBL,
as it is the ﬁrst time that stratiﬁcation other than according to
clinical parameters for T-LBL will be used. In addition to the NHL-
BFM, other groups and other treatment centers might evaluate,
validate, and use the parameters described in the current report.
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